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A Plea for Biobanking of All Equivocal
Melanocytic Proliferations
H. Peter Soyer, MD, FACD; Lynlee L. Lin, BSc; Tarl W. Prow, PhD
In 2005, in an editorial in the Archives of Dermatology (now
JAMADermatology), wemade a plea for a combined diagnos-
tic approach tohistopathologic anddermoscopic evaluation.1
Weconcludedoureditorialwith the followingstatement1 (p211):
Histopathology, as every other purelymorphologicmethod,
is limited by methodologic drawbacks and sometimes by prac-
titioners’ personal limitations.Todayweareon the edgeofanew
biology in histopathology, and one can foresee that our beloved
classic morphology will soon be replaced by new technologies.
In themeantime, a combinedmorphologic approach linkingder-
moscopy and histopathology might be helpful for pathologists
to come tomore reliable diagnostic conclusions for patients and
their physicians.
And it is encouraging to see that indeed there is an increased
awareness by colleagues dealing with problematic and bor-
derline melanocytic proliferations that has led to a more re-
fined clinicodermoscopic and pathologic approach in the in-
terpretation of these lesions.
In the present editorial, we take the opportunity to make
anotherplea,namely, aplea forbiobankingofall equivocalme-
lanocytic proliferations. This plea is based on our interpreta-
tionof thepioneering studybyMalvehyandcolleagues2 in this
issue of JAMA Dermatology.
This original morphologic
study combining expertise in
dermoscopy and dermatopa-
thology will doubtless lead to a redefinition of the way tradi-
tional gross pathologic procedures are carried out for equivo-
cal pigmented skin lesions. We commend the authors of this
seminal, albeit contested, work, and we agree with them that
highlyspecializedprovidersof skinpathologicanalysiswill em-
bracemore advanced sampling technologies that usedermos-
copy guidance in the future, thus reflecting the paradigmatic
shift fromconventional surgicalpathologicanalysis tomolecu-
larpathologicanalysis, inorder toremaincompetitiveand,most
importantly, do themost good for our patients.
Why Biobanking?
The new credo of personalizedmedicine has already reached
dermato-oncology, and more and more of our patients with
melanomaareno longer asking about their prognosis or about
an estimated survival time but whether their melanoma is a
BRAF melanoma. Whereas this specific query can be an-
swered rather easily by performing, for example, the cobas
4800BRAFV600MutationTest (Roche)on formalin-fixedpar-
affin-embedded samples, there is a growing need for frozen
tissue samples for thosemolecular andgenetic tests thatmight
be available by the time today’s primary melanomametasta-
sizes in 5 or 10 years’ time. There is no doubt that biobanking
is one of the central tools for clinical and translational
medicine.3 The challenge is, of course, to organize the bio-
bank samplingwithminimaldisruption to thebusydailyprac-
ticeofdealingwithpatientswithmelanomasandclinically sus-
picious pigmented skin lesions. Malvehy and colleagues2
correctly note that their sophisticated protocol for biobank
sampling has been developed for “experienced research cen-
ters.” Of interest is a recent publication by Caenazzo and
colleagues4 on the ethical issues of balancing the rights of the
individual and the interest of society in biobanking research
on oncological residualmaterial. Biobank research cannot be
conducted without considering arguments for obtaining the
donors' consent.Theauthorsdescribedthetypeofconsent that
“would be appropriate in this context, considering the ethi-
cal principles of donation, solidarity, protection of the do-
nors' rights and the requirements of scientific progress.”4 The
authors concluded that an important ethical aspect in regard
to the role of biobanking is the need to encourage sample
donation.
Dermoscopy, Dermatopathology, and Targeted Sampling
The “ex vivo dermoscopic-oriented sampling of melanoma”
protocol has been designed in close collaboration by a group
of dermatologists and dermatopathologists, all of them with
great expertise in dermoscopy, with the specific aim of not
jeopardizing the conventional histopathologic diagnosis.
The protocol includes conservation of the thickest part of
the lesion for measuring the Breslow index. The authors
nicely showed that by creating a “dermoscopic melanoma
map” they were able to successfully sample the nonthickest
part of the lesion and also avoided sampling areas that con-
tain dermoscopic melanoma-specific features whose
absence could interfere with the dermatopathologist’s ability
to render a conclusive diagnosis. Unfortunately, their tar-
geted sampling protocol excludes small melanomas, dermo-
scopically equivocal lesions, and other melanocytic lesions
for which they suspect that the histopathologic evaluation
may prove difficult. The authors fear that insufficient mate-
rial will be provided for the pathological assessment and that
this may lead to clinical and medicolegal consequences.5
Also, the issue of shave biopsies or saucerizations was not
mentioned at all. Only completely excised lesions can be
included. All these exclusion criteria are, in our estimation,
serious limitations for the purpose of “biosampling” even in
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a highly specialized melanoma center because as many sus-
picious melanocytic skin proliferations as possible should be
biosampled. However, one can imagine that, inspired by this
original and authentic work by Malvehy and colleagues,2
several dermatology and/or pathology teams worldwide will
come up with their own solutions and protocols for molecu-
lar sampling of suspicious melanocytic proliferations.
Microbiopsies forMolecular Sampling
Recently, we have developed a submillimeter skin punch bi-
opsy device forminimally invasive and suture-free skin sam-
pling that extracts approximately 1500 keratinocytes and 5 to
10 ng DNA and RNA for molecular diagnosis in dermatology
and dermato-oncology (L. L. Lin, BSc; T. W. Prow, PhD; A. P.
Raphael, PhD; R. L. Harrold III, MD; C. A. Primiero, BSc; A. B.
Ansaldo, BE; H. P. Soyer, MD, FACD; unpublished data; May
2013). Our microbiopsy device is 0.50 mmwide and 0.15 mm
thickandresults ina0.21 ± 0.04-mm-widepuncturesite invol-
unteer skin as measured using reflectance confocal micros-
copy. In a research letter in this issue of JAMA Dermatology,
we have demonstrated theminimal impact that the choice of
microbiopsysitehasonthehistopathologicdiagnosisofagiven
melanocytic proliferation.6 The size of microbiopsy defects
measured in this study was comparable to those of other ar-
tifactsmoreor less commonly seen in routine sectioned speci-
mens, and the inherent diagnostic difficulties for the derma-
topathologistencounteredwiththehistopathologicassessment
of amicrobiopsiedmelanocytic skin lesion can easily be over-
come by ordering of multiple levels.
Synopsis and Utopia
Microbiopsy devices have already been developed for breast
and intestinal tissue on the basis of the step change advances
in micromanufacturing and in molecular and genetic testing.
The ingenious outcomes are meaningful analyses that can be
obtained nowadays even froma few cells.We foresee thatmi-
crobiopsieswill become a feasiblemolecular sampling option
forbiobankingofequivocalmelanocyticproliferations, andbe-
cause of the simplicity of the sampling procedure, a multi-
tude of melanocytic lesions can be biobanked easily in due
course. In addition, the use of these samples can be maxi-
mized with nucleic acid amplification followed by whole ge-
nome and transcriptome sequencing that will be made open
source, thereby creating a sort of virtual biobank in the cloud
in the spirit of theubiquitousbigdata concept. If only 1or a few
expert laboratories in collaborationwith a fewmelanomacen-
tersdoesthis,ourpatientswillbenefit throughopensourcedata
analysis linking the microbiome, virome, genome, transcrip-
tome, and thenoncodingRNAworldwith the clinical andder-
moscopicphenotypes. Suchanapproachwill probably change
our understanding of the enigmatic and so often fateful na-
ture of melanocytic proliferations to the better. One possible
outcomemaybe amolecular profile assigned to a specific der-
moscopic morphology, ie, a molecular imaging profile, that
could give us insight into themolecular pathologic character-
istics of a lesion using just dermoscopy imaging. Biobanking
ofmelanomasandequivocalmelanocyticproliferationswill lose
its research status soon and become a standard of care in der-
mato-oncology as an integral part of personalizedmedicine.
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